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Toll-like receptors (TLRs) are expressed on all major subsets of liver cells. Both exogenous ligands derived from pathogens, and
endogenous ligands that are products of cellular injury, engage these receptors and activate aspects of innate immunity. These
receptors play a role in viral and parasitic infections of the liver, in ischemia-reperfusion injury, and in toxic liver damage,
promotingantipathogenimmunitybutalsohepatocellularinjuryandﬁbrogenesis.However,TLRsmayalsoparticipateinnegative
feedback that limits tissue injury. In the complex environment of the liver, TLRs participate in pathologic cascades involving
multiple cell types, manifesting their eﬀects both through cell-autonomous actions, and via cellular crosstalk. In this paper we
survey the involvement of TLRs in these diverse processes.
1.Introduction
The Toll-like receptors (TLRs) form a multigene family
that is well conserved between human and murine species.
These receptors are cell surface or intracellular receptors for
molecular signatures characteristic of viruses, bacteria, and
parasites, including features of their nucleic acids, proteins,
and lipid and carbohydrate components. The pathogen-
associated molecular patterns (PAMPs) engaged by TLRs
are basic features of these microorganisms that cannot
readily be modiﬁed by genetic mutation, thus that are
features of entire categories of microorganisms. A prime
example is the lipopolysaccharide (LPS) endotoxin of the
cell walls of Gram-negative bacteria, which engages a cell
surface member of the TLR family, TLR4, activating multiple
downstreamsignaling pathwaysthatresultinthesynthesisof
cytokines and interferons. TLRs share functional similarities,
and downstream eﬀector mechanisms, with other pathogen
recognition systems such as the RIG-I like proteins that
detect viral nucleic acids, and the NOD-like receptors that
respond to bacterial cell wall elements.
All of the known TLRs are expressed in the liver, and
this is likely to be biologically important since the liver
receives blood from the intestine, which is an internal body
surfaceexposedtoPAMPsderivedfromharmlesscommensal
bacteria in the gut lumen as well as potentially antigenic
components of the diet and from time to time, invasive
microorganisms.
Hepatic injury is associated with an increase of liver
exposure to bacterial products, but the healthy liver is able
to develop a tolerance towards bacterial products coming
from the gut. Speciﬁcally, the exposure of liver sinusoidal
endothelial cells (LSECs) to low levels of LPS results in the
loss of their TLR4 expression, resulting in LPS insensitivity
[1]. This eﬀect is not limited to homologous ligand, since
the administration of the TLR3 ligand, poly I:C, also
downregulates LPS sensitivity on Kupﬀer cells (KCs) [2].
In hepatocytes, this mechanism depends on SOCS-1 which
interacts with TIRAP in the TLR signaling pathway [3].
In the liver, immune responses are complicated by the
immune competence of many populations of cells, including
an unusual assembly of lymphocytes in which Natural Killer
(NK) cells and CD8+ T cells are unusually abundant, as well
as Dendritic Cells (DCs), KCs, LSECs, hepatic stellate cells
(HSCs), hepatocytes, and bile duct cells. Any or all of these
cell types may respond to TLR signals, and any of them may
actasantigen-presentingcells(APCs)thatcanengageTcells.
Inﬂammatory or immune pathologies that converge on the
hepatocyte (such as hepatocellular injury and regeneration),
or the HSC (ﬁbrosis, cirrhosis), very likely involve other cell
types. For example, innate immune signals may activate KCs,
theKCsmayelaboratecytokines,andthesecytokinesmayact2 Gastroenterology Research and Practice
on HSCs, either promoting or suppressing ﬁbrogenesis. Here
we address the issue of how TLRs may be involved in such
cellular cross-talk in liver immunopathology.
The analysis would be more straightforward if each liver
cell type expressed a characteristic set of TLRs. However,
thereisverylittlesegregationofTLRexpression: studieswith
both puriﬁed cell cultures and cell lines support the idea that
all liver cell populations express essentially all TLRs at the
mRNA level. Comprehensive studies of the responsiveness of
individual cell types to a full range of TLR ligands are few.
At present, no speciﬁc liver cell population can be identiﬁed
as central in TLR-mediated pathologies. Furthermore, the
eﬀects of TLR ligation vary from cell to cell.
WhileTLRscaninitiateinnateimmunecascadesthrough
the recognition of exogenous PAMPs, they also recognize
endogenous signals released by damaged cells. Thus, dying
cells release RNA, which can engage TLR3; nuclear DNA
that can engage TLR9; and HMBG1 (high mobility group
box protein 1) that can engage TLR4. This gives endogenous
injury signals, like exogenous PAMPs, access to both the
MyD88 and the TRIF signaling pathways. This raises the
possibility that immunopathology, initiated by a TLR-
mediated response to a PAMP, can result in tissue damage
thatsustainsitselfthroughotherTLR-mediatedmechanisms.
In the liver, TLRs are involved in infections (HCV, HBV),
but also in “sterile injury” models including Concanavalin
A (ConA)-induced hepatitis, bile duct ligation, partial hep-
atectomy, acetaminophen toxicity, and ischemia-reperfusion
injury. TLRs and particularly TLR4 play a key role in liver
regeneration, in alcoholic liver injury, in the development of
steatosis, and in the recruitment of activated CD8+Tc e l l st o
the hepatic sinusoids [4]. In addition, tissue culture models
reveal some pathways of cell-cell interaction triggered by
TLR engagement. In our own experiments, TLR2, TLR3,
and TLR4 activation of human Kupﬀer cells resulted in
diﬀerential secretion of IL-18 and IL-10, which coordinately
regulated the activation and IFN-γ synthesis of cocultured
human liver NK cells [5].
Downstream eﬀects of TLR signaling in diverse models
include hepatocellular injury, measured most often as an
increase in serum alanine aminotransaminase (ALT); ﬁbro-
genesis, measured by the upregulation of timp-1, collagen,
and α-smooth muscle actin expression; steatosis quantiﬁed
mainly by hematoxylin eosin saﬀron (HES) histochemical
staining of lipid droplets; liver regeneration assessed via
hepatocyte mitotic activity and the restoration of liver mass;
and anti-pathogen eﬀects such as suppression of HCV
replicationormalariaparasiteload.Thedetailedarticulation
of these numerous interacting pathways is still some way
in the future. We can, however, explore some structuring
ideas through the current literature, and try to discern some
common themes in TLR involvement in liver pathology.
2. TLRs Responding to Endogenous Ligands
While it is clear that TLRs may respond to molecules
released by injured cells, there are also experimental models
induced by mechanical or toxic stresses that do involve
bona ﬁde bacterial products, and these cases need to be
distinguished from the involvement of TLRs in “sterile
injury” where the ligands are truly endogenous. Bacterial
endotoxemia contributes directly to liver injury in apparent
unrelated hepatic pathologies such as cholestasis, chronic
alcoholic hepatitis, or steatohepatitis. In bile duct-ligated
animals, pretreatment with intraperitoneal LPS upregulates
the expression of TLR4 and MyD88 [6], as well as CD14
and CD68 [7], and confers hypersensitivity to LPS in ﬁbrotic
livers. The increase in proinﬂammatory cytokines (TNF-α
and IL-6) secretion was observed as early as two hours after
LPS administration in BDL rats. These models of liver injury
in apparently unrelated hepatic pathologies.
In other models, TLRs are involved but the source of
their ligands is less clear. For example, after hemorrhagic
shock, endogenous damage-associated molecular patterns
(DAMPs) are released from cells during traumatic injury
allowing them to interact with TLRs. In particular, TLR4
expression is required on bone marrow-derived cells and on
liver parenchymal cells to detect systemic and remote organ
response to hemorrhagic shock [8]. However, it is unclear if
this model also results in LPS translocation across the gut.
In nonalcoholic steatohepatitis, a direct link exists
between TLR4 and Kupﬀer cells in the pathogenesis of liver
injury. In a methionine choline deﬁciency (MCD) diet-
induced model of steatohepatitis, histological evidence of
liver inﬂammation, portal endotoxemia and enhanced TLR-
4 expression occurs in wild-type mice fed the MCD diet. In
contrast, injury and lipid accumulation markers were signif-
icantly lower in TLR4 mutant mice. Targeted destruction of
Kupﬀer cells with clodronate liposomes blunted histological
evidence of steatohepatitis and prevented increases in TLR4
expression, induced increases in the production of TNF-
α, ICAM-1, and signiﬁcantly impaired the development of
hepatic injury. In support of the idea that the expression of
TLR4 on Kupﬀer cells is essential for injury, destruction of
these cells also prevented increases in TLR-4 expression [9].
In alcoholic liver disease, low expression of the anti-
inﬂammatory factor GILZ (Glucocorticoid Induced Leucin
Zipper) in monocytes contributes to liver inﬂammation and
hypersensitization to LPS. GILZ messenger RNA (mRNA)
levelswerelowerintheliversofpatientswithAHversusthose
without AH. A treatment with glucocorticoids enhances
GILZ expression and abrogates macrophage sensitivity to
LPS and subsequent proinﬂammatory cytokine secretion
[10].
In this model, TLR4 is required for liver injury but
MyD88, its principal downstream eﬀector, is not necessary
for injury. Alcohol feeding results in a signiﬁcant increase
in liver injury in wild-type (wt), TLR2−/−, and MyD88−/−
but not in TLR4−/− mice [11]. The expression of inﬂamma-
tory mediators (TNF-α and IL-6) and the TLR4 coreceptors
(CD14 and MD2) signiﬁcantly increases in livers of alcohol-
fed wt, TLR2−/−,o rM y D 8 8 −/−, but not in TLR4−/−
mice, compared to controls. Alcohol feeding also induces
nuclear factor-kappaB activation in a TLR4-dependent,
but MyD88-independent manner. This shows that while
TLR4 deﬁciency was protective, MyD88 deﬁciency failed to
prevent alcohol-induced liver damage and inﬂammation by
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pathway involving the adapter protein TRIF, and also IRF-7,
was involved.
A very recent report shows that inﬂammation occurs
after both major trauma and infection injury [12]. Mito-
chondrial DAMPs (MTDs) include formyl peptides and
mitochondrial DNA. Mitochondrial DNA activates human
polymorphonuclear neutrophils (PMNs) through TLR9.
The assessment of MMP8 protein expression—a marker of
neutrophil inﬁltration—was increased in whole livers of rats
injected intravenously with mitochondrial DAMPs whereas
control rats showed no evidence of hepatic inﬂammation.
After tissue trauma, mitochondrial DAMPs that express
at least the two molecular signatures, formyl peptides, and
mtDNA, act on pattern recognition receptors recognizing
bacterial PAMPs. These activate PMN in the circulation
rather than at speciﬁc targets, inciting nonspeciﬁc attack
on multiple organs, including the liver, while suppressing
chemotactic responses to infective stimuli.
Other intracellular “alarmins” may similarly be impor-
tantafterinjury,andotherimmunecellsprobablyrespondto
MDTs.Injury-derivedMDTs,however,areclearlyrecognized
by innate immunity using pattern recognition receptors that
alternatively sense bacteria. This novel model may explain
why responses to these ancient “enemies within” released by
injury can mimic sepsis.
3.TLRs May Mediate Injury-Limiting as well as
Injury-PromotingPathways
One good example of this “injury limiting eﬀect” is the
response of conventional DCs to TLR9 ligation by DNA
released from cells during ischemia-reperfusion injury. By
secreting IL-10, these DCs respond to damage-associated
patterns released by injured cells, providing the host with
protection from progressive damage, potentially limiting
tissue injury in the presence of dying cells [13].
Similarly, the ligation of TLR9 inhibits NF-κB binding
activity in T cells, and increases survival of mice in a model
of ConA-induced hepatitis. Liver injury—as measured by
circulating ALT levels—decreases after pretreatment with
CpG oligodeoxynucleotides sequences that can engage TLR9
[12] .H o w ev e rt h i si sn o tap r o pe rtyo fT L R 9i ng e n e ra l ,s i n c e
this receptor promotes liver injury in acetaminophen injury
[14], in ischemia/reperfusion [13], and in nonalcoholic
steatohepatitis [15].
In acetaminophen injury, acetaminophen treatment
results in hepatocyte death and the free DNA released from
apoptotic hepatocytes activates TLR9. This triggers a signal-
ingcascadethatincreasestranscriptionofthegenesencoding
pro-IL-1β and pro-IL-18 in LSECs. TLR9 antagonists and
aspirin reduced mortality from acetaminophen hepatotox-
icity [16]. In ischemia/reperfusion injury, TLR4, but not
TLR2, is speciﬁcally required to initiate the tissue-damaging
cascade, as manifested by liver function (serum ALT lev-
els), pathology, and local induction of proinﬂammatory
cytokines/chemokines (TNF-α, IL-6, and CXCL10) [14].
In a model of liver injury induced with acetaminophen,
therewasMyD88-dependentrecruitmentofneutrophilsinto
the liver, as assayed by the abundance of the neutrophil
enzyme myeloperoxidase (MPO) [17]. This was due not
to TLR signaling, but required the IL-1R expressed on
non-bone marrow-derived cells. Sterile neutrophilic inﬂam-
mation is thought to contribute to the pathogenesis of
acute ischemia-induced liver injury and to impair healing.
Blocking such sterile inﬂammation is a potentially attractive
strategy to limit the damage of acute sterile inﬂammation
and to stop the ongoing damage in chronic inﬂammation
from progressing to liver injury.
In a model of segmental liver ischemia-reperfusion
injury, the treatment of wt mice with an inhibitory cytosine-
guanosine dinucleotide (iCpG) sequence reduced signiﬁ-
cantly the serum ALT and inﬂammatory cytokines after liver
ischemia-reperfusioninjury,andthesamewasseeninTLR9-
deﬁcient mice. Liver damage was mediated by bone marrow-
derived cells because wt mice transplanted with TLR9−/−
bone marrow were protected from injury. Injury in wt mice
partly depends on TLR9 signaling in neutrophils, which
enhanced production of ROS, IL-6, and TNF-α. In vitro,
DNA released from necrotic hepatocytes increased cytokine
secretion in liver nonparenchymal cells and neutrophils
through a TLR9-dependent mechanism. Inhibition of both
TLR9 and HMGB1 caused maximal inﬂammatory cytokine
suppression in neutrophil cultures and conferred even
greater protection from ischemia-reperfusion injury in vivo
[13].
In diet-induced obesity, TLR9−/− mice show less steato-
hepatitis and liver ﬁbrosis than wt mice. Among inﬂamma-
tory cytokines, IL-1β production is suppressed in TLR9−/−
mice. Kupﬀer cells produce IL-1β in response to CpG
oligodeoxynucleotides leading to steatosis and inﬂammation
[15]. Similarly, CpG DNA promotes liver injury in the
presenceofD-Gal,promotingapoptoticdeathinhepatocytes
[18]. Taken together, these data do not yield a simple model
for the involvement of TLR9 signaling in modulating liver
injury. The most straightforward interpretation is that TLR9
has both pro- and anti-injury eﬀects, depending on the cell
types concerned and their interactions.
Two single nucleotide polymorphisms (SNPs) of the
TLR4 gene emerge as conferring protection from ﬁbrosis
progression compared to wt. The study of the functional
linkage of this SNP to HSCs responses show that both
HSCs from TLR4−/− mice and a human HSC line recon-
stituted with either TLR4 D299G and/or T399I cDNAs
were hyporesponsive to LPS stimulation compared to those
expressing wt TLR4, as assessed by the expression and
secretion of LPS-induced inﬂammatory and chemotactic
cytokines (MCP-1 and IL-6). The conclusion is that TLR4
D299G and T399I SNPs that are associated with protection
from hepatic ﬁbrosis reduce TLR4-mediated inﬂammatory
and ﬁbrogenic signaling and lower the apoptotic threshold
of activated HSCs. These ﬁndings provide a mechanistic link
that explains how speciﬁc TLR4 SNPs may regulate the risk
of ﬁbrosis progression [19].
Conversely, when TLRs do not intervene in injury-limi-
ting pathways, they can promote liver failure through direct
interaction with mediators promoting injury. Although the
receptor for advanced glycosylation end products (RAGEs)
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identiﬁcation of direct recognition of HGMB1 with diﬀerent
TLRs has conﬁrmed the wide range of possible interactions.
The HMGB proteins have been described to play a role as
late mediators of lethality in sepsis as well as in cells
undergoing necrosis, but not in cell death due to apoptosis
nor from cells exposed to inﬂammatory cytokines. HMGB1
is a nuclear factor, which is released from injured cells,
including hepatocytes. It is argued that HMGB1 interacts
with TLR4, since TLR4 defective (C3H/HeJ) mice exhibits
less damage in the hepatic ischemia-reperfusion model than
wt C3H/OuJ mice [20].
TLR9 sits at the interface of microbial and sterile
inﬂammation by detecting both bacterial and endogenous
DNA. Released in the extracellular compartment during
acute inﬂammatory responses, HMGB1 also interact with
TLR2 [21] and TLR9 [22]. Unlike LPS, which primarily
increasedtheactivityofIKK-β, HMGB1 exposure resulted in
activation of both IKK-α and IKK-β. Kinases and scaﬀolding
proteins downstream of TLR2 and TLR4 were involved
in the enhancement of NF-κB-dependent transcription by
HMGB1. Transfections with dominant negative constructs
show that TLR2 and TLR4 were both involved in HMGB1-
induced activation of NF-κB. Interactions of HMGB1 with
TLR2andTLR4mayprovideanexplanationfortheabilityof
HMGB1 to generate inﬂammatory responses that are similar
tothoseinitiatedbyLPS[21].TLR3mayalsoacttomodulate
aspectsofliverinﬂammationbyactivatingNKTcellsthatcan
eliminate gamma-delta T cell through apoptosis [23], thus
changing the cellular makeup of inﬂammatory inﬁltrates.
Stellate cells are subject to regulation both through
their own TLRs and via cross-talk. Thus, stellate cells are
maintained in an undiﬀerentiated state by interaction with
fresh LSEC acting via VEGF and NO [24].
As mammalian cells undergo apoptosis, genomic DNA
undergoes signiﬁcant modiﬁcations, which include caspase-
mediated cleavage but also aberrant methylation and oxida-
tive damage. Such changes may result in enrichment in CpG
sequences in comparison to random DNA from the human
genome. As a sensor for cell injury, HSCs phagocytose
apoptotic hepatocyte bodies with subsequent regulation of
TGF-β and collagen-α1m R N A[ 25]. The consequence is
TLR9-dependent HSC diﬀerentiation as well as a stop signal
to retain HSC at sites of hepatocyte apoptosis [26]. Other
groups have shown that TLR4 downstream activation can
have important functional consequences on hepatic stellate
cells. TLR4 activation in hepatic stellate cells sensitizes
HSCs to TGF-β-induced signals and upregulates chemokine
secretion and induces chemotaxis of Kupﬀer cells [27, 28]. In
particular, LPS induces signal transduction and upregulates
chemokines(IL-8,CCL2)andadhesionmolecules(VCAM-1
and ICAM-1) in activated human HSCs from patients with
hepatitis C virus induced cirrhosis [27].
4. TLRs inHost Defense against
Hepatocellular Pathogens
TLRs were ﬁrst identiﬁed in Drosophila melanogaster as a
genetic element, the lack of which predisposed adult ﬂies to
lethalfungalinfection[29].Recognitionofthesigniﬁcanceof
suchnonrearrangingreceptorsledMedzhitovandJanewayto
search for homologous molecules in the mouse and human
genomes, [30], while a convergent line of research using
positional cloning identiﬁed the receptor for LPS as a TLR
[31]. While additional roles of these molecules continue
to emerge, the principal phenotypes of TLR-deﬁcient mice
are associated with increased susceptibility to infection. The
TLRs also play this role in the liver.
Viruses interacting with host cells can modulate expres-
sion and function of TLRs. In chronic hepatitis C virus
(HCV) infected patients, expression of TLR4, 7 and 8 is
increased in peripheral CD14+ cells together with circulating
levels of TNF-α, IL-6, and IL-12p35. The incubation of
PBMC with HCV core protein triggers the expression of
TLR2 and suppresses TLR4 and TLR7 [32]. Activation of
nonparenchymal cells such as KCs and LSECs with TLR
ligands leads to the secretion of IFN-β,w h i c hp o w e r f u l l y
suppresses HCV replication [33]. In the same way, while the
expressionofmessengerRNAencodingallTLRsisdetectable
in HSCs, the spectrum of TLR ligands, which are capable to
induce secretion of antiviral cytokines, is restricted to TLR3
in human HSCs. Moreover, such ligation results only in IFN-
β suﬃcient to suppress the replication of either LCMV or
HCV, but not in the synthesis of relevant amounts of other
IFNs (i.e., neither IFN-γ nor IFN-α)[ 34].
These host defense-promoting eﬀects of TLR engage-
ment are not only antiviral. TLR2, 3, 4, and 9 ligands can
reducetheliverloadofparasitesinmurinePlasmodiumyoelii
infection. In particular, CpG as a TLR9 ligand causes an 88%
decrease in hepatic parasite load, and in mice challenged
with 100 sporozoites, results in complete suppression of
parasitemia for at least 14 days [35]. This eﬀect of CpG
was accompanied by increases in hepatic IL-12 and TNF-
α as well as IFN-γ, and decreases in IL-10 and TGF-β1.
The eﬀect of Kupﬀer cell depletion is to abrogate these
eﬀects and restore parasite load. It therefore seems likely
that CpG was eliciting a three-way cross-talk among liver
cells: the activation of Kupﬀer cells resulting in IL-12 and
TNF-α; the activation of either NK cells or T cells since
these are the main sources of IFN-γ; and hepatocytes, the
cells in which the parasite develops or fails to develop
under conditions stimulating TLR2, 3, 4 or particularly
TLR9. Plasmodium berghei infection induces IL-12 through
MyD88-dependent pathways, but not TLR2, 4, and 6 [36].
This secretion of IL-12 induces hepatocyte killing through
hepaticCD1d-independentDX5+Tcellsthroughaperforin-
dependent mechanism [37]. Hepatic Listeria monocytogenes
infectioninducesIL-12andIL-18productioninKupﬀercells
through TLR/MyD88 signaling, which stimulates NK cells to
produce IFN-γ, and this is critical for eradication of Listeria
organisms from the host [38, 39].
The evolutionary history of TLRs, and their role in
directly binding to PAMPs, may suggest that the primary
TLR function is to initiate the innate immune response
to pathogens and to condition accessory cells in ways that
promote the induction of adaptive immunity. However, TLR
activation can also be a mechanism through which responses
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Adenovirus vector, in which both the innate and adaptive
immune response depend on TLR2 and TLR9 [40]. The
key point is that Adenovirus was able to activate signaling
throughERK1/2inKupﬀercells,butthatsuchactivationwas
independent of TLR2 and MyD88. However, the sustained
activation of ERK1/2 required both TLR2 and MyD88. With
respecttoNF-kBactivation,earlyactivationrequiredMyD88
but not TLR2, while sustained activation required both
MyD88 and TLR2. Cytokine and chemokine responses also
required MyD88 and TLR2. It is not entirely clear how this
works, but the most likely model is that the innate immune
responses, initiated by direct activation of ERK1/2, release
endogenous ligands that signal via a receptor coupled to
MyD88, and for full immune activation also act via TLR2.
Such ligands have not yet been identiﬁed.
A strikingly similar role for TLR signaling in sustaining
aninnateresponsewasfoundinaverydiﬀerentexperimental
model. In poly-microbial septic peritonitis, in the absence
of any exogenous viral stimulus, the initial cytokine and
chemokine burst was increased in TLR3−/− mice; however
thisresponsewasmorerapidlycurtailed,andthesemicewere
protected from the lethal eﬀects of sustained inﬂammation
[41]. The same was found in an ischemic gut injury model.
Furthermore,theinvestigatorsfoundthatRNAreleasedfrom
apoptotic neutrophils could activate macrophages from wt,
but not from TLR3−/− mice, suggesting that a positive feed-
back loop was acting through neutrophil recruitment and
apoptosis, activation of macrophages by released RNA, and
macrophage activation leading to sustained inﬂammation.
Integrating these elements, we arrive at a picture where
TLRs have two distinct roles in responses to exogenous
infection. First, they may act directly as sensors of PAMPs
synthesized by pathogens, and in this role they are likely
to initiate the ﬁrst steps in an immune response. But in
addition, TLRs may amplify or sustain an immune response
by signaling in response to exogenous molecular products
of tissue damage, such as DNA (TLR9), HMGB1 (TLR4),
and RNA (TLR3). In the early days of the recognition of
the importance in immune activation of diverse signals
apart from T and B cell receptor ligation, it is argued that
lymphocytes are responding not to “nonself” molecules but
to “danger”, which can only be construed as a metaphor
for tissue injury [42]. Alternatively, it was counter-argued
that such “danger” could be better understood as molecular
signatures characteristic of pathogens, the signals that were
subsequently named PAMPs [43]. Now, through an analysis
of the diverse roles of TLRs in infectious disease in the liver
and elsewhere, we can see that both positions were correct.
What is more, “danger” and PAMPs activate and sustain
inﬂammation through the same family of receptors.
5.TLRSignalsAreTransmittedvia
Cell-CellCrosstalk
Cross-talk is when a TLR acts on one cell but the biological
eﬀect is transmitted to a diﬀerent cell type. Few examples of
TLR-driven cross-talk have been explored in the liver, but
the examples that exist implicate several major cell types in
interactions of this kind.
We have studied the impact of TLR signaling in human
Kupﬀer cells, obtained from fresh human liver lobes sampled
during the process of living donor liver transplantation.
This procedure yields intrahepatic leukocytes that are rich in
human KC and human liver NK cells, and these were used in
cross-talk experiments ex vivo. Engagement of TLR3 resulted
in powerful NK cell activation in KC-NK cell cocultures, but
not when the two cells were separated in a Transwell tissue
culture system [5]. Stimulation via TLR2 or TLR4 resulted in
less dramatic NK cell activation, but the full activation of NK
cells was restored by blocking IL-10. Thus the TLR ligands
that activated the MyD88 signaling pathway induce IL-10
along with proinﬂammatory cytokines, and inhibit NK cells;
the TLR3 ligand, working only via the TRIF pathway, does
not induce IL-10. Conversely, the main NK cell-activating
signal is IL-18, synthesized in response to all three TLR
ligands [5]. Thus, Kupﬀer cells are integrating signals from
diﬀerent TLRs, and integrating them to modulate NK cell
activity via cross-talk.
While these experiments in human cells emphasize the
eﬀects of IL-18 on NK cells, we have also explored IL-18
action in murine NK-T cells. In these cells, also, it is a
powerful activating factor [44]. Hepatitis C virus-encoded
coreproteinisabletointerferewithTLR-mediatedactivation
of human Kupﬀer cells. Speciﬁcally, core binds to TLR2,
and this can induce diverse proinﬂammatory cytokines
[45, 46], but also IL-10. We also show that HCV core
acting on human Kupﬀer cells can suppress other antiviral
mechanisms, including type 1 IFN and the upregulation
of TRAIL [24]. Thus, viruses can exploit TLRs to disable
immunity.
One important negative regulatory eﬀect of cross-talk
is the recently discovered action of LSEC in suppressing
the transdiﬀerentiation of HSCs via nitric oxide [24]. The
key point is that only resting LSECs have this eﬀect,
since endothelial cells harvested from a liver undergoing
capillarization do not suppress HSC trans-diﬀerentiation.
The LSECs are inﬂuenced in their capacity to make nitric
oxide by VEGF, which therefore acts as an antiﬁbrotic factor.
While there is no evidence relating to the inﬂuence of TLRs
in NO synthesis by LSECs, there is a strongly analogous case.
In neurovascular endothelium, NO synthesis was induced by
Neisseria meningitidis, and this eﬀect was blocked by anti-
bodies to TLR2 and TLR4—but not to TLR9 [47]. Extrap-
olating to the liver, where LSECs are constitutively exposed
to LPS concentration ranging from 100pg/mL to 1ng/mL, it
seems likely that such low level TLR4 engagement supports
NO synthesis and maintains HSCs in their resting state.
TLR4 signaling enhances TGF-β1 in HSCs by downregu-
lating the TGF-β1 pseudo-receptor Bambi, thus stimulating
ﬁbrosis. Quiescent hepatic stellate cells are the predomi-
nant targets through which TLR4 ligands—but not TLR2
ligands—are required to promote ﬁbrogenesis. In quiescent
HSCs, TLR4 activation upregulates chemokine secretions
induces chemotaxis of KCs, and allows for unrestricted
activation by KCs [28].
We can therefore see signals that are initiated by TLRs
participating in cross-talk between KCs and NK cells, and
between KCs and HSCs, and we can envisage mechanisms6 Gastroenterology Research and Practice
through with TLRs modulate cross-talk between KCs and
NK-T cells, and between LSECs and HSCs. Since the
expression of TLRs is almost universal among liver cell
subsets, the documentation of such TLR-driven cell-cell
interactions is sure to increase.
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